OptiMed of Kalamazoo Provides COVID Boosters for Ages 12+

KALAMAZOO, Mich., January 6, 2022 (OptiMed Health Partners) – The Center for Disease Control and Prevention (CDC) as of January 5th, 2022 recommends COVID-19 boosters for individuals ages 12-17 to maintain immunity longer. COVID-19 boosters help strengthen protection against Omicron and other SARS-CoV-2 variants.

“It is critical that we protect our children and teens from COVID-19 infection and the complications of severe disease,” states Dr. Rochelle Walensky, CDC Director. “Today, I endorsed ACIP’s vote to expand eligibility and strengthen our recommendations for booster doses. We now recommend that all adolescents aged 12-17 years should receive a booster shot 5 months after their primary series. This booster dose will provide optimized protection against COVID-19 and the Omicron variant. I encourage all parents to keep their children updated with CDC’s COVID-19 vaccine recommendations.”

To be eligible for the booster, it must be after five months after the primary series was completed. The primary series is two (2) prior doses of mRNA vaccine (Pfizer or Moderna) - OR - one (1) prior dose of J&J vaccine. Visit vaccines.gov to find a location closest to you. OptiMed offers clinics every Tuesday and throughout the year.

About the COVID Clinics: By choosing to vaccinate against COVID-19, you are helping to protect yourself, your family, your friends, and the community. OptiMed offers vaccine clinics throughout the year.

About OptiMed:  OptiMed Health Partners, headquartered in Kalamazoo, Michigan, is an independently owned and operated national healthcare organization. For more than 25 years, OptiMed leverages personalized attention to detail to deliver customized solutions that optimize patient outcomes while partnering with other healthcare organizations to usher in a new standard of excellence. To learn more about OptiMed's innovative and personalized care, visit www.optimedhp.com.

上一篇
上一篇

OptiMed Health Partners Announces Promotion of Rusti Greis to Vice President, Business Development

下一个
下一个

OptiMed Health Partners Offers Monoclonal Antibody Infusion Treatment for COVID Positive Patients